Skip to main content
. 2016 Jul 5;34(25):2997–3004. doi: 10.1200/JCO.2015.65.4582

Fig 2.

Fig 2.

(A) Progression-free (PFS) and (B) overall survival (OS) of patients receiving three cycles of rituximab plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) plus radiotherapy (R-CHOP3RT) with prolonged follow-up. 5- and 10-year estimates are included. Median follow-up was 12 years.